Steve Elms
CIK 1250195 · last filed 2026-03-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LOXO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
489 FIFTH AVENUE, 10TH FLOOR
NEW YORK, NY 10017
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADMA | Director | 2,136,750 | $11.05 | $23.61M | -$17.76M | 19 | 2026-03-09 |
| MRKR | Director | 328,338 | $0.94 | $308.6K | $2.04M | 8 | 2025-11-19 |
| Elevation Oncology, Inc. (ELEV) Delisted | Director | — | $0.36 | — | $0 | 3 | 2025-07-24 |
| Zosano Pharma Corp (ZSAN) Delisted | Director | 78,307 | $0.56 | $43.7K | $0 | 5 | 2021-06-14 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 5,570,102 | — | — | $18.42M | 8 | 2019-02-15 |
| PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Director | 201,000 | — | — | $0 | 4 | 2016-05-31 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 35,155 | $221.38 | $7.78M | $0 | 1 | 2015-04-22 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | 1,650,156 | $0.54 | $890.4K | $3.39M | 3 | 2014-09-04 |
| MAP Pharmaceuticals, Inc. (MAPP) Delisted | Director | 0 | $28.11 | $0 | -$33.8K | 5 | 2010-05-24 |
Recent Filings · Page 3 of 6
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-10 | MRKR | Grant (A) | +12,658 | $0 | EDGAR |
| 2021-03-18 | MRKR | Buy (P) | +1,142,857 | $2.00M | EDGAR |
| 2021-03-01 | ADMA | Grant (A) | — | $0 | EDGAR |
| 2020-06-29 | Zosano Pharma Corp (ZSAN) Delisted | Grant (A) | +7,500 | $0 | EDGAR |
| 2020-06-05 | Zosano Pharma Corp (ZSAN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-01 | ADMA | Grant (A) | +7,500 | $0 | EDGAR |
| 2020-03-03 | ADMA | Grant (A) | +7,500 | $0 | EDGAR |
| 2019-08-08 | MRKR | Grant (A) | — | $0 | EDGAR |
| 2019-07-18 | Zosano Pharma Corp (ZSAN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-15 | ADMA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.